The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future. Recently, the U.S. Food and Drug Administration (FDA) accepted ...
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...
The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...
Tibetan tingsha bells are used as a brief pre-event grounding intervention, leveraging sustained high-frequency resonance to ...
Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions. As the 2026 ASCO Genitourinary (GU) Cancers ...
The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.
For many facing a cancer diagnosis, the "why" can be the most elusive piece of the puzzle. When Lauren Yerkes was diagnosed ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 ...
Elite performance and cancer survivorship both demand tolerance of uncertainty, disciplined preparation, and the ability to recover psychologically when outcomes hinge on minor missteps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results